Session Description
Successful pharmaceutical drug development requires identifying ranges of doses providing an acceptable efficacy response while not causing unacceptable intolerance or toxicity. Dr. Gould shall describe a novel application of Bayesian model averaging (BMA) methodology to the construction of dose ranges with a high probability of clinical acceptability that can be read directly from simple graphical displays. The ranges are based on posterior distributions of efficacy and toxicity outcomes from possibly different unknown functional dose–response relationships and different likelihoods.
Presented by:
A. Lawrence Gould, PhD
MERCK & Co.
